The Patient Protection and Affordable Care Act, known as the ACA, calls for quality initiatives such as comparative effectiveness research to increase effective, appropriate, and high-value care. This paper, by NMDP/Be The Match Payor Policy and other staff, reviews the main provisions of the ACA with specific attention to their impact on the field of hematopoietic cell transplantation. The authors discuss the new forms of payment reform that providers need to be aware of, particularly in the Medicare program. Other topics include new insurance coverage protections and increased access to care for patients, as well as payment reform, health insurance markets, and expanded Medicaid coverage.
Farnia S, et al. Curr Hematol Malig RepChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Impact of the Affordable Care Act on HCT
Jan 2014